Research programme: anti-EGFR x anti-CD3 bispecific antibodies - BioAtla
Latest Information Update: 26 May 2021
At a glance
- Originator BioAtla
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 19 May 2021 Research programme - anti-EGFR x anti-CD3 bispecific antibodies is available for licensing as of 19 May 2021. https://www.bioatla.com/strategic-relationships/
- 19 May 2021 BioAtla plans to file an IND application with the US FDA in 2022
- 19 May 2021 BioAtla plans to conduct IND enabling studies by 2021